Mitotech S.A. Announces its Ophthalmic Scientific Advisory Board

Share Article

Mitotech S.A., a Luxembourg based clinical stage biotechnology company pursuing treatment for Dry Eye Syndrome, announced today its Ophthalmic Scientific Advisory Board. Mitotech’s most advanced clinical program targeting Dry Eye Syndrome recently achieved positive results in a Phase II study conducted in the U.S. Appointment of the Ophthalmic Scientific Advisory Board reaffirms company’s focus on development of ophthalmic drugs.

Mitotech S.A., a Luxembourg based clinical stage biotechnology company focused on age-related disorders, announced today that it established its Ophthalmic Scientific Advisory Board. Mitotech’s most advanced clinical program targeting Dry Eye Syndrome recently achieved positive results in a Phase II study conducted in the U.S. Appointment of the Ophthalmic Scientific Advisory Board reaffirms company’s focus on development of ophthalmic drugs.

"Dry eye is becoming an important indication for biotechnology and pharmaceutical companies and we recognize that by putting it in the frontline of our development program,” said Natalia Perekhvatova, Chief Executive Officer of Mitotech S.A. “We also continue clinical development of our lead compound SkQ1 for other ophthalmic indications such as uveitis and dry AMD. We believe that innovative mechanism of action of SkQ1 could help patients suffering from a variety of inflammatory ophthalmic indications. The innovation is a continuous process that constantly poses challenging scientific and technological problems and our new Scientific Advisory Board will be of great help along the way with their invaluable knowledge and experience.”

Mitotech S.A. appointed three members to the newly formed Ophthalmic Scientific Advisory Board - Dr. Penny Asbell, Dr. Robert Ritch and Dr. James Rosenbaum.

Dr. Penny Asbell is a Professor of Ophthalmology at Mount Sinai School of Medicine and Director of the Cornea Service and Refractive Surgery Center. Dr. Asbell is currently on the Board of Directors of the International Society of Refractive Surgery and is Past-President of the Contact Lens Association of Ophthalmologists. Dr. Asbell serves on Mount Sinai's Committee on the Ethical Practices in Research and the New York County Medical Society's Special Committee on Women Physicians. Dr. Asbell received her M.D. from the State University of New York at Buffalo, interned in Internal Medicine at Yale-New Haven Hospital, then trained as a resident and fellow in Ophthalmology and Immunology at the New York University Medical Center.

Dr. Robert Ritch holds the Shelley and Steven Einhorn Distinguished Chair in Ophthalmology and is Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai (NYEE). He has devoted his career to broadening our understanding of the underlying etiologies and mechanisms of glaucoma and innovation in its medical, laser, and surgical treatment. Dr. Ritch received his B.A. cum laude from Harvard College and an M.A. in cell biology from Harvard University. He received his M.D. from Albert Einstein College of Medicine and, after an internship at St. Vincent’s Medical Center and a residency in Ophthalmology at Mount Sinai School of Medicine, received fellowships in glaucoma from the Heed Foundation and the National Institutes of Health.

Dr. James T. Rosenbaum has spent more than 30 years studying ocular inflammatory disease including animal models of uveitis. His research interests are complemented by his direction of a clinic devoted to patients with ocular inflammatory diseases including uveitis, scleritis, orbital inflammation, and steroid sensitive optic neuropathy. He has authored more than 400 peer reviewed publications and more than 75 chapters or invited publications. He has been honored by the Association for Research in Vision and Ophthalmology and by the International Uveitis Study Group Eye Foundation with their highest awards. Dr. Rosenbaum received his medical degree from Yale Medical School in New Haven, CT. He completed his medicine residency and rheumatology fellowship at Stanford Medical Center in Stanford, CA.

About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for the treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria addressed antioxidants. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Natalia Perekhvatova
Mitotech
+352 271127060
Email >
Visit website